E-Newsletter - December 2017

ALLIANCE RESEARCH IN SPOTLIGHT  
2017 ASH MEETING DECEMBER 9-12

The American Society of Hematology (ASH) is the world's largest professional society serving both clinicians and scientists who are working to conquer blood diseases. ASH represents more than 17,000 members from nearly 100 countries. The Alliance for Clinical Trials in Oncology will present an array of novel data from many of its hematology studies during the 59th ASH Annual Meeting and Exposition December 9-12 in Atlanta, GA. Many of these data will help change the delivery of hematologic cancer care or help elucidate the underlying cause and effect relationships seen in this field.

Here's a snapshot of studies that were presented.
 
CALGB (Alliance) 10603
The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations
Lead author: Richard M. Stone, MD
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II
Location: Sunday, December 10, 6 pm-8 pm, Georgia World Congress Center, Bldg A, Lvl 1, Hall A2 (Poster)
Learn more about the trial.

CALGB (Alliance) 10603
An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations
Lead author: Richard A. Larson, MD
Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Innovative AML Treatment with Approved Agents
Location: Saturday, December 9, 12 pm, Bldg C, Lvl 3, Georgia BR 1-3, Georgia World Congress Center (Oral)
Learn more about the trial.

CALGB (Alliance) 10603
Concomitant Use of Midostaurin with Strong CYP3A4 Inhibitors: An Analysis from the Ratify Trial
Lead author: Taoufik Ouatas, PhD
Session: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III
Location: Monday, December 11, 6 pm-8 pm, Bldg A, Lvl 1, Hall A2, Georgia World Congress Center (Poster)
Learn more about the trial.
 
CALGB (Alliance) 10603
Prognostic Impact of NPM1/FLT3-ITD Genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study
Lead author: Konstanze Döhner, MD
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Advances in Frontline Therapy: Induction, Consolidation, and Maintenance
Location: Sunday, December 10, 5:30 pm, Bldg B, Lvl 5, Murphy BR 1-2, Georgia World Congress Center (Oral)
Learn more about the trial.
 
CALGB (Alliance) 8461, 20202  
Molecular Landscape and Clinical Features of Acute Myeloid Leukemia (AML) with Complex Karyotype (CK)
Lead author: Krzysztof Mrózek, MD, PhD
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Location: Saturday, December 9, 5:30 pm-7:30 pm, Bldg A, Lvl 1, Hall A2, Georgia World Congress Center (Poster)
Learn more about the trials - CALGB 8461, and CALGB 20202.
 
CALGB (Alliance) 8461, 20202
Mutational Landscape and Clinical Outcome Associated with Different Rearrangements Involving 11q23/MLL in De Novo Acute Myeloid Leukemia (AML)
Lead author: Bill Marius, MD, PhD
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster III
Location: Monday, December 11, 6 pm-8 pm, Bldg A, Lvl 1, Hall A2, Georgia World Congress Center (Poster)
Learn more about the trials - CALGB 8461, and CALGB 20202.
 
CALGB (Alliance) 8461, 20202
Acute Myeloid Leukemia (AML) Patients with an Isolated Trisomy Display Increased Frequency of Spliceosome Mutations  
Lead author: Bhavana Bhatnagar, DO
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II
Location: Sunday, December 10, 6 pm-8 pm, Georgia World Congress Center, Bldg A, Lvl 1, Hall A2 (Poster)
Learn more about the trials - CALGB 8461, and CALGB 20202.
   
CALGB (Alliance) 8461, 9665, 20202  
Recurrent Genetic Variants of Long Non-Coding RNAs Independently Associate with Clinical Outcome of Younger Adults with Cytogenetically Normal Acute Myeloid Leukemia
Lead author: Dimitrios Papaioannou, MD
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Location: Saturday, December 9, 5:30 pm-7:30 pm, Bldg A, Lvl 1, Hall A2, Georgia World Congress Center (Poster)
Learn more about the trials - CALGB 8461, CALGB 9665 and CALGB 20202.
 
CALGB (Alliance) 50904
Randomized Phase 2 Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine and Bortezomib Induction and Maintenance Therapy in Patients (pts) with Previously Untreated High Risk Follicular Lymphoma (FL): Results from CALGB 50904 (Alliance)
Lead author: Kristie A. Blum, MD
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Follicular Lymphoma, First Line
Location: Sunday, December 10, 5:30 pm; Bldg C, Lvl 1, Hall C1, Georgia World Congress Center (Oral)
Learn more about the trial.
   
 
ALLIANCE FOUNDATION TRIALS
AFT-08
A Phase I, Open-Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma
Lead author: Peter Martin, FRCPC, MD, MSAcute Myeloid Leukemia (AML) Patients with an Isolated Trisomy Display Increased Frequency of Spliceosome Mutations
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Novel Agents and Upfront Approaches
Location: Saturday, December 9, 3:15 pm, Bldg A, Lvl 4, A411-A412, Georgia World Congress Center (Oral)  
Learn more about the trial.

 

For other articles in the December issue of the Alliance E-News newsletter, see below.